Navigation Links
Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
Date:8/11/2011

THE WOODLANDS, Texas, Aug. 11, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Wedbush 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011 at 1:15 p.m. Eastern Time in New York City.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the event may be accessed on Lexicon's corporate website at www.lexpharma.com.  An archived version of the webcast will be available for 30 days after the event on the company's website.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
2. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
4. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
7. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
8. Lexicon to Provide First Quarter 2011 Financial Results
9. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
10. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
11. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... and INDIANAPOLIS , June 9, 2017 ... with diabetes. In a further effort to help spread ... by this condition, the International Diabetes Federation (IDF) and ... have come together for the second phase of the ... programme (BRIDGES 2), reaffirming their commitment to helping people ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/5/2017)... 2017 Kohll,s Pharmacy & Homecare is the first distributor ... States . The Raizer is a simple battery operated ... to an almost-standing position within a few minutes. ... assistant and does not require any extra effort besides ... child can operate it, and lightweight and portable ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated ... selected as the partner of choice by Amtrak to fulfill several projects in ... medium- and long-distance intercity service in the contiguous United States. Security Executives at ...
(Date:6/20/2017)... MD (PRWEB) , ... June 20, 2017 , ... ... “joy of living” aboard the line’s latest all-inclusive boutique ship, S.S. Joie de ... she was built specifically for cruising France’s Seine River and designed small enough to ...
(Date:6/20/2017)... ... June 20, 2017 , ... The law firm of ... his installation as the president of the DuPage County Bar Association’s Board of Directors. ... Dinner June 9 at the Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney ...
(Date:6/19/2017)... ... June 19, 2017 , ... The joyful summer wedding season is ... a humdinger. A warm winter and wet spring have created ideal conditions for mosquitoes ... to be swatting away pesky mosquitoes when a bride and groom are saying their ...
(Date:6/19/2017)... ... 2017 , ... Haute Beauty welcomes Dr. Hayes Gladstone, a ... and wellness experts. , With two decades of experience in reconstructive and aesthetic ... restoration. , Heading the successful Gladstone Clinic in San Ramon, ...
Breaking Medicine News(10 mins):